• Corpus ID: 30707958

IL 1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NFk B Activation

  title={IL 1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NFk B Activation},
  author={Zhuo-nan Zhuang and Huai-qiang Ju and Mitzi Aguilar and Takashi Gocho and Hao Li and Tomonori Iida and Harold Lee and Xiaoqiang Fan and Haijun Zhou and Jianhua Ling and Zhongkui Li and Jie Fu and Min Wu and Min Li and Davide Melisi and Yoichiro Iwakura and Kesen Xu and Jason B. Fleming and Paul J. Chiao},
Purpose: Constitutive NF-kB activation is identified in about 70% of pancreatic ductal adenocarcinoma (PDAC) cases and is required foroncogenicKRAS-inducedPDACdevelopment inmouse models. We sought to determine whether targeting IL-1a pathway would inhibit NF-kB activity and thus suppress PDAC cell growth. Experimental Design: We determined whether anakinra, a human IL-1 receptor (rhIL-1R) antagonist, inhibited NF-kB activation. Assays for cell proliferation, migration, and invasion were… 

Figures from this paper

TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy.

Immunotherapeutic approaches of IL‐1 neutralization in the tumor microenvironment

The role of IL‐1 agonistic molecules in tumor progression and their potential to serve as targets in anti‐tumor immunotherapeutic approaches are discussed.

Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.

The results of this study suggest that genetic silencing or inhibition of TAK1 kinase activity in vivo is a potential therapeutic approach to reversal of the intrinsic chemoresistance of pancreatic cancer.

Identification of an Autoregulatory Feedback Pathway Involving Interleukin-1α in Induction of Constitutive NF-κB Activation in Pancreatic Cancer Cells*

It is found that an autocrine mechanism accounts for the constitutive activation of NF-κB in metastatic human pancreatic cancer cell lines and a possible missing mechanistic link between inflammation and cancer is suggested.

Secreted Interleukin-1α Induces a Metastatic Phenotype in Pancreatic Cancer by Sustaining a Constitutive Activation of Nuclear Factor-κB

The findings further support the possible link between inflammation and cancer and suggest that IL-1α may be a potential therapeutic target for treating pancreatic adenocarcinoma.

Why not treat human cancer with interleukin-1 blockade?

  • C. Dinarello
  • Biology, Medicine
    Cancer and Metastasis Reviews
  • 2010
Clinical trials of interleukin-1 blockade should be initiated, particularly as an add-on therapy of patients receiving antiangiogenesis-based therapies, given the availability of three therapeutic agents for limiting IL-1 activity, the safety of blockingIL-1, and the clear benefit of blocking IL- 1 activity in animal models of metastasis and angiogenesis.

Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice.

The majority of human pancreatic cancers have activating mutations in the KRAS proto-oncogene. These mutations result in increased activity of the NF-κB pathway and the subsequent constitutive

Activation of nuclear factor-κB in acinar cells increases the severity of pancreatitis in mice.

The level of NF-κB activation correlates with the severity of acute pancreatitis in mice and the findings indicate that strategies to inactivate NF-σB might be used to treat patients with acute or chronic pancreatitis.

An Undesired Effect of Chemotherapy

The data demonstrate that gemcitabine induces CXCR4 expression in two PC cell lines (MiaPaCa and Colo357) in a dose- and time-dependent manner and reinforce the role of CXCL12/CX CR4 signaling in gemcitABine resistance and point toward an unintended and undesired effect of chemotherapy.

NF-κB in carcinoma therapy and prevention

Cumulative evidence implicates NF-κB in cell survival, inflammation, angiogenesis, spread and therapeutic resistance during tumor development, progression and metastasis of carcinomas.

NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia.

It is shown that in normal human epidermal cells both NF-kappaB and oncogenic Ras trigger cell-cycle arrest, and IkappaBalpha circumvents restraints on growth promotion induced by oncogens Ras and can act with Ras to induce invasive human tissue neoplasia.